Success Stories Sterionics | NicheVision | FMI Technologies | Summit Data Communications | 7signal | Nervomatrix | Quest Medical Imaging |Fluence | Adjuvant Polymers | APTO Orthopaedics | Intellirod Spine | Nervive OES Plus Company develops technology to predict readmission risk OES Plus has developed a technology to identify patients with a high risk of readmission within 30 days. It can also provide recommendations for appropriate intervention levels, and it has the ability to monitor patients' behavior during this intervention. In fact, OES Plus has the leading predictive technology for determining Congestive Heart Failure (CHF) readmission risk. One user interface contains multiple data platforms of patient information through OES Plus, and that interface can be customized to fit the needs of individual health systems or users. The end goal of this information is to provide a higher quality of service to patients and to provide necessary care to avoid readmission when possible.